BIODESIX INC
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
BDSX$10.02-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
Balance Sheets
(in thousands, except share data)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $26,284 | $43,088 |
| Accounts receivable, net of allowance for doubtful accounts of $65 and $118 | 7,679 | 5,065 |
| Other current assets | 5,720 | 5,181 |
| Total current assets | 39,683 | 53,334 |
| Non‑current assets | ||
| Property and equipment, net | 27,867 | 5,848 |
| Intangible assets, net | 7,911 | 9,797 |
| Operating lease right-of-use assets | 1,745 | 2,973 |
| Goodwill | 15,031 | 15,031 |
| Other long-term assets | 6,859 | 5,923 |
| Total non‑current assets | 59,413 | 39,572 |
| Total assets | $99,096 | $92,906 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities | ||
| Accounts payable | $2,929 | $1,685 |
| Accrued liabilities | 7,710 | 8,218 |
| Deferred revenue | 324 | 962 |
| Current portion of operating lease liabilities | 252 | 1,543 |
| Current portion of contingent consideration | 21,857 | 10,341 |
| Current portion of notes payable | 51 | 49 |
| Other current liabilities | 293 | 41 |
| Total current liabilities | 33,416 | 22,839 |
| Non‑current liabilities | ||
| Long‑term notes payable, net of current portion | 35,225 | 25,004 |
| Long-term operating lease liabilities | 25,163 | 5,254 |
| Contingent consideration | — | 18,645 |
| Other long-term liabilities | 712 | 558 |
| Total non‑current liabilities | 61,100 | 49,461 |
| Total liabilities | 94,516 | 72,300 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2023 and 2022) issued and outstanding | — | — |
| Common stock, $0.001 par value, 200,000,000 authorized; 96,235,883 (2023) and 77,614,358 (2022) shares issued and outstanding | 96 | 78 |
| Additional paid‑in capital | 424,050 | 387,948 |
| Accumulated deficit | (419,566) | (367,420) |
| Total stockholders' equity | 4,580 | 20,606 |
| Total liabilities and stockholders' equity | $99,096 | $92,906 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.